61145-37-7

Upstream product

• 3068-34-6 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl chloride 
• 73982-52-2 2-Acetamino-3,4,6-tri-O-acetyl-1,2-bisdesoxy-1-S-isothioureido-β-D-glucopyranose 
• 107-14-2 chloroacetonitrile 
• 3068-34-6 Acetic acid (2R,3S,4R,5R,6R)-3-acetoxy-2-acetoxymethyl-5-acetylamino-6-chloro-tetrahydro-pyran-4-yl ester 
• 51224-18-1 S-thiouronium 2-N-acetamido-3,4,6-tri-O-acetyl-2-deoxy-1-thio-β-D-glucopyranoside hydrochloride 

Downstream Products

• 61145-38-8 S-cyanomethyl 2-N-acetamido-2-deoxy-1-thio-β-D-glucopyranoside 
• 75204-31-8 2-acetamido-1-thio-(S-2-imido-2-methoxyethyl)-2-deoxy-β-D-glucopyranoside 

Relevant academic research and scientific papers

DRUG DELIVERY

A drug delivery vehicle comprising a vesicle conjugated to one or more targeting groups, wherein the targeting groups comprise an oligosaccharide which is Lewis A or Lewis B or a mimetic thereof, or a pharmaceutically acceptable salt or PEGylated form of the oligosaccharide : (I) wherein R represents the pointof attachment to the vesicle.10

A triply divergent reagent for glycoprotein synthesis

Chemical synthesis of glycoproteins through three different strategies, from the same reagent, is herein described. The flexibility of this system, which allows the comparison of different linkage motifs between the same glycan and protein, is shown by one-step diversification of a GlcNAc-ylating reagent and its application in both site-specific and non-site-specific glycoprotein synthesis to create different conjugates from common representative protein scaffolds.

INFLAMMATION IMAGING AND THERAPY

An imaging agent comprising a conjugate of an oligosaccharide moiety with an imaging moiety. The oligosaccharide is Lewis A or Lewis B or a mimetic thereof, or a pharmaceutically acceptable salt or PEGylated form of Lewis A or Lewis B or its mimetics. Lewis A and Lewis B and its mimetics are also provided for use in the therapeutic treatment of inflammatory diseases, autoimmune diseases and cancer.